Launch of Website; Corporate Update

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the launch of its new corporate website, marking another step in the Company's scientific and corporate evolution and placing its proprietary P140 autoimmune platform at the forefront of its strategy.

P140 is a first-in-class peptide-based therapy designed to address the root cause of autoimmune and inflammatory diseases.

Unlike current therapies that aim to suppress or modulate immune activity, P140 selectively restores immune balance without compromising healthy immune function.

By directly targeting key pathways involved in immune tolerance, P140 represents a new therapeutic category: an immunormalizer.

This targeted mechanism offers the potential for enhanced safety, durability of response, and applicability across multiple autoimmune conditions.

In conclusion, this unique mechanism aims to rebalance immune homeostasis, enabling patients to achieve durable remission rather than temporary symptom control.

As also outlined in the new website, ImmuPharma is developing a next-generation companion diagnostic to P140 designed to identify and monitor patients with a high level of precision.

Unlike conventional static autoantibody tests, this tool integrates multi-layered diagnostic logic to guide both patient selection and treatment adaptation.

This innovative approach enables accurate pre-treatment stratification and in-treatment monitoring, addressing a critical unmet need in autoimmune disease management.

Please visit ImmuPharma's website to learn the whole story! Link: www.immupharma.co.uk

Potential Partnerships and Path Toward Commercialisation

Following the recent key milestone announcement on 1 September 2025, confirming that a new groundbreaking P140 patent has been filed, providing the opportunity to extend patent protection for the compound until 2045, the Company is engaging with a number of potential partners. The Company has a comprehensive data room which all potential partners, on the signing of a Confidential Disclosure Agreement, have the opportunity to access the most recent data and clinical findings, in order to carry out the appropriate due diligence necessary.

Further updates, as appropriate, will be communicated to the market between now and our stated objective of completing a deal by the end of 2025.

Financial Update

ImmuPharma's cash runway has recently been extended into H2 2026, by the exercise of warrants and enhanced monthly cash receipts under the current Lanstead Capital sharing agreement, the final settlement for which is expected in November. ImmuPharma has no intention to raise further funds and will look to further strengthen its cash position as a result of deals with potential partners.

Tim McCarthy, Chief Executive Officer of ImmuPharma, commented:

"Our new website reflects the exciting transformation taking place at ImmuPharma, scientifically, corporately, and strategically. The advances within our P140 autoimmune platform represent a paradigm shift in how autoimmune therapies will be diagnosed and treated and underlines the strong scientific foundation and commercial potential of our technology.

A strong statement in our new website but reflective of our focus within the autoimmune technology space. "Our mission is simple yet bold: to pave the way to a cure, where most existing approaches focus only on relieving symptoms"."